BridgeBio Pharma, Inc.: BEYONTTRA (acoramidis), the First Near Complete TTR Stabilizer (=90%), Approved by the European Commission to Treat ATTR-CM
BridgeBio Pharma, Inc.: BEYONTTRA (acoramidis), the Fir…
4 months ago
finanznachrichten.de
BridgeBio Pharma, Inc. Présente les résultats positifs détaillés de l'étude de phase 3 Attribute-CM sur l'acoramidis pour les patients atteints de cardiomyopathie amyloïde à transthyrétine (ATTR-CM) au Congrès 2023 de la Société européenne de cardiologie
BridgeBio Pharma, Inc. Présente les résultats positifs détaillés de l'étu…
Aug 27, 2023
zonebourse.com
BridgeBio Pharma, Inc.: Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
BridgeBio Pharma, Inc.: Acoramidis Shows Statistically Significant Im…
11 months ago
finanznachrichten.de
BridgeBio Pharma, Inc.: First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
BridgeBio Pharma, Inc.: First Participant Dosed with Acoramidi…
10 months ago
finanznachrichten.de
BridgeBio Pharma, Inc.: BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma, Inc.: BridgeBio Pharma Announces U.S. Food an…
May 2, 2024
finanznachrichten.de
BridgeBio Pharma : l'acoramidis réduit les événements cardiovasculaires cumulatifs dès le premier mois chez les patients atteints de cardiomyopathie amyloïde à transthyrétine
BridgeBio Pharma : l'acoramidis réduit les événements cardiovasc…
5 months ago
zonebourse.com
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by A…
1 week ago
YahooMaham Fatima
BridgeBio Pharma, Inc.: BridgeBio Announces Commercial Progress…
Jan 13, 2025
finanznachrichten.de
BridgeBio Pharma, Inc.: BridgeBio Announces Infigratinib Is the Firs…
Sep 17, 2024
finanznachrichten.de
Acoramidis: A Potential Breakthrough Treatment for Trans…
Jul 18, 2023
labroots.com
BridgeBio Pharma and Helsinn Group Obtain FDA Approval for T…
Jun 1, 2021
nasdaq.com
BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug
Nov 25, 2024
investors.com
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase …
3 weeks ago
YahooSimply Wall St
3:48
From Diagnosis to Treatment: Eric's ATTR-CM Journey
181 views11 months ago
YouTubeBridgeBio
BridgeBio Pharma, Inc.: BridgeBio Announces CFO Succession
11 months ago
finanznachrichten.de
1:27
Significance of Ventricular Hypertrophy in ATTR-CM
62 viewsDec 4, 2024
YouTubeBridgeBio
1:05
Some Signs and Symptoms of ATTR-CM
179 viewsNov 23, 2024
YouTubeBridgeBio
This Biotech Is On A Triple-Digit Run, And Shows No Signs Of Slo…
3 months ago
investors.com
0:42
What Causes Hereditary ATTR CM?
23 viewsNov 23, 2024
YouTubeBridgeBio
1:52
How BridgeBio Transformed Compliance With Egnyte’s GxP Co…
114 views10 months ago
YouTubeEgnyte
鉅亨速報 - Factset 最新調查：BridgeBio Pharma IncBBIO-US …
10 months ago
yahoo.com
37:34
BridgeBio Pharma (BBIO) @ JPM 2026 第44届摩根大通医疗保健会议
7 views1 month ago
bilibilibili_42520431755
59:21
Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Am…
211 viewsJan 9, 2025
YouTubePeerView CME
1:49
BridgeBio Raised $135M to Fund 10 Drugs at Once—Here’s How
133 views7 months ago
YouTubeMelissa Bime
4:51
ATTRUBY - FDA NDA approval - 2024-11-22
214 viewsDec 11, 2024
YouTubeInside Drug Discovery
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Str…
1 week ago
YahooGuruFocus News
The News That Could Stoke BridgeBio, Up 80% This Year
5 months ago
investors.com
1:21
BridgeBio Introduces - On Rare
62 viewsMar 3, 2025
YouTubeBridgeBio Pharma
48:37
EP 212: A hub-and-spoke model for accelerating rare disease drug dev…
74 views4 months ago
YouTubeSano Genetics
LLNL and BridgeBio announce trials for supercomputing-discovered ca…
5 months ago
llnl.gov
See more videos
Static thumbnail place holder